Asceneuron SA

Asceneuron SA is a Switzerland-based clinical stage biotech company with a focus on developing orally bioavailable therapeutics for neurodegenerative disorders. With the mission of targeting the root cause of neurodegeneration, Asceneuron's pipeline aims to address a wide range of neurodegenerative diseases such as orphan tauopathies, Alzheimer’s, and Parkinson’s disease. The company has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson’s disease and Alzheimer’s. Established in 2012, Asceneuron has garnered significant support from a renowned syndicate of investors including Sofinnova Partners, M Ventures, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and Kurma Partners. Their most recent Series C investment of $100.00M on 16 July 2024 saw participation from a diverse group of investors including Novo Holdings, OrbiMed, GlaxoSmithKline, MERL Ventures Fund, EQT Life Sciences, and Johnson & Johnson Innovation – JJDC, reflecting industry confidence in the company's potential. Asceneuron's dedication to addressing the significant unmet medical needs in neurodegenerative disorders and the strong backing from prominent investors position it as a notable player in the biotechnology and health care sectors. For more information, visit www.asceneuron.com.